Upcoming Events

5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 23 - 24, 2024 - Boston Marriott Long Wharf, Boston, MA

IMS is pleased to announce that the 5th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 23-24, 2024 in Boston, MA.

Tentative Agenda

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – East Coast

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – East Coast

March 27, 2024 - Webinar

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Tentative Agenda

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast

April 10, 2024 - Webinar

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Tentative Agenda

Educational Workshop, Buenos Aires, Argentina

Educational Workshop, Buenos Aires, Argentina

April 19 - 20, 2024 - Sheraton Buenos Aires & Convention Center, Buenos Aires, Argentina

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

 

Preliminary Agenda

2nd Annual Genomics Meeting

2nd Annual Genomics Meeting

July 12 - 13, 2024 - Hilton Barcelona, Barcelona, Spain

The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. The publication with the results and recommendations from this meeting has been submitted for review. Building upon this success, the Second IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

In addition to which, this day and a half-long meeting will include sessions on:

  • Risk Stratification validation
  • Genomically targeted therapies
  • New technologies
  • Genomic Biomarkers for stratification of clinical studies
  • New clinical trials for patients with HR disease
21st IMS Annual Meeting

21st IMS Annual Meeting

September 25 - 28, 2024 - Rio de Janeiro, Brazil

Mark your calendars for the 21st IMS Annual Meeting in Rio de Janeiro, Brazil!

The 21st IMS Annual Meeting will take place in Rio de Janeiro, Brazil from September 25-28, 2024.

More details will be available soon. 

 

Translational Research Award

Career Development Award

Coming soon! – ARTEMIS

Analytic Research and daTa Exchange for Myeloma International Studies

Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

About Our Publications

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

See All Publications

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events